Published in Curr Gene Ther on December 01, 2005
Gene therapy of the rheumatic diseases: 1998 to 2008. Arthritis Res Ther (2009) 0.87
Therapeutic strategies for SLE involving cytokines: mechanism-oriented therapies especially IFN-gamma targeting gene therapy. J Biomed Biotechnol (2010) 0.82
Notes on the kidney and its diseases for the neurologist. J Neurol Neurosurg Psychiatry (2007) 0.75
EULAR recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 3.37
Heat shock protein 70 kDa: molecular biology, biochemistry, and physiology. Pharmacol Ther (1998) 3.36
T cell receptor alpha/beta expressing double-negative (CD4-/CD8-) and CD4+ T helper cells in humans augment the production of pathogenic anti-DNA autoantibodies associated with lupus nephritis. J Immunol (1989) 3.10
Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet (2001) 2.95
Interleukin-17 and systemic lupus erythematosus: current concepts. Clin Exp Immunol (2009) 1.95
IgE secretion by Epstein-Barr virus-infected purified human B lymphocytes is stimulated by interleukin 4 and suppressed by interferon gamma. Proc Natl Acad Sci U S A (1989) 1.89
Oncogene-induced replication stress preferentially targets common fragile sites in preneoplastic lesions. A genome-wide study. Oncogene (2007) 1.85
Imatinib for the treatment of refractory, diffuse systemic sclerosis. Rheumatology (Oxford) (2008) 1.83
Pathogenic anti-DNA autoantibody-inducing T helper cell lines from patients with active lupus nephritis: isolation of CD4-8- T helper cell lines that express the gamma delta T-cell antigen receptor. Proc Natl Acad Sci U S A (1990) 1.83
Altered pattern of TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells from patients with systemic lupus erythematosus. Deficient expression of the T cell receptor zeta chain. J Clin Invest (1998) 1.80
A pilot study of endothelial dysfunction and aortic stiffness after interleukin-6 receptor inhibition in rheumatoid arthritis. Atherosclerosis (2011) 1.78
Molecular basis of deficient IL-2 production in T cells from patients with systemic lupus erythematosus. J Immunol (2001) 1.68
TNF-α antagonists beyond approved indications: stories of success and prospects for the future. QJM (2010) 1.57
B cells from patients with systemic lupus erythematosus display abnormal antigen receptor-mediated early signal transduction events. J Clin Invest (1996) 1.56
Glutamate levels and activity of the T cell voltage-gated potassium Kv1.3 channel in patients with systemic lupus erythematosus. Arthritis Rheum (2008) 1.51
Clinical use of the measurement of soluble cell adhesion molecules in patients with autoimmune rheumatic diseases. Clin Diagn Lab Immunol (1997) 1.48
Defective CD3-mediated cell death in activated T cells from patients with systemic lupus erythematosus: role of decreased intracellular TNF-alpha. Clin Immunol Immunopathol (1996) 1.46
Fc epsilon receptor type I gamma chain replaces the deficient T cell receptor zeta chain in T cells of patients with systemic lupus erythematosus. Arthritis Rheum (2001) 1.44
Prophylactic use of antibiotics and immunisations in patients with SLE. Ann Rheum Dis (2002) 1.41
Small airways dysfunction in systemic sclerosis. A controlled study. Chest (1992) 1.39
Epstein-Barr virus induces normal B cell responses but defective suppressor T cell responses in patients with systemic lupus erythematosus. J Immunol (1983) 1.37
TCR/CD3 complex-mediated signal transduction pathway in T cells and T cell lines from patients with systemic lupus erythematosus. J Immunol (1995) 1.36
Management of Behçet disease: a systematic literature review for the European League Against Rheumatism evidence-based recommendations for the management of Behçet disease. Ann Rheum Dis (2008) 1.32
Immunoregulatory disorders associated with hereditary angioedema. I. Clinical manifestations of autoimmune disease. J Allergy Clin Immunol (1986) 1.31
Abnormal NF-kappa B activity in T lymphocytes from patients with systemic lupus erythematosus is associated with decreased p65-RelA protein expression. J Immunol (1999) 1.30
Retinal toxicity in long term hydroxychloroquine treatment. Ann Rheum Dis (1996) 1.27
Overexpression of the heat shock protein 70 enhances the TCR/CD3- and Fas/Apo-1/CD95-mediated apoptotic cell death in Jurkat T cells. J Immunol (1997) 1.26
Protein kinase C-theta participates in the activation of cyclic AMP-responsive element-binding protein and its subsequent binding to the -180 site of the IL-2 promoter in normal human T lymphocytes. J Immunol (2001) 1.22
Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum (1997) 1.21
Immunopathogenesis and spectrum of infections in systemic lupus erythematosus. Semin Arthritis Rheum (1996) 1.16
IL-17-producing T cells in lupus nephritis. Lupus (2011) 1.15
Complement inhibitor, complement receptor 1-related gene/protein y-Ig attenuates intestinal damage after the onset of mesenteric ischemia/reperfusion injury in mice. J Immunol (2001) 1.14
Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behçet disease. Ann Intern Med (2004) 1.13
Generation and biochemical analysis of human effector CD4 T cells: alterations in tyrosine phosphorylation and loss of CD3zeta expression. Blood (2001) 1.13
B-cell kinase lyn deficiency in patients with systemic lupus erythematosus. J Investig Med (2001) 1.13
Hypersensitivity reactions to carboplatin administration are common but not always severe: a 10-year experience. Oncology (2001) 1.12
Biological properties and regulation of IL-10 related cytokines and their contribution to autoimmune disease and tissue injury. Clin Immunol (2012) 1.12
Deficient gamma-interferon production in patients with systemic lupus erythematosus. Arthritis Rheum (1986) 1.11
Heterogeneous nuclear ribonucleoprotein D0B is a sequence-specific DNA-binding protein. Biochem J (1999) 1.10
Characterization of murine complement receptor type 2 and its immunological cross-reactivity with type 1 receptor. Int Immunol (1990) 1.10
Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J Immunol (1991) 1.09
ZAP-70 and SLP-76 regulate protein kinase C-theta and NF-kappa B activation in response to engagement of CD3 and CD28. J Immunol (2001) 1.08
Suppression of murine SLE by oral anti-CD3: inducible CD4+CD25-LAP+ regulatory T cells control the expansion of IL-17+ follicular helper T cells. Lupus (2009) 1.08
Activated T lymphocytes in the peripheral blood of patients with systemic lupus erythematosus induce B cells to produce immunoglobulin. Clin Exp Rheumatol (1988) 1.08
The effect of olive oil and fish consumption on rheumatoid arthritis--a case control study. Scand J Rheumatol (1991) 1.06
NIH conference. Systemic lupus erythematosus. Ann Intern Med (1991) 1.06
Human in vitro allogeneic responses. Demonstration of three pathways of T helper cell activation. J Immunol (1990) 1.03
Renal and metabolic complications of undifferentiated and lymphoblastic lymphomas. Medicine (Baltimore) (1981) 1.02
Altered signal transduction in SLE T cells. Rheumatology (Oxford) (2007) 1.02
T cell-antigen-presenting cell interactions in human systemic lupus erythematosus. Evidence for heterogeneous expression of multiple defects. J Immunol (1993) 1.02
Monoclonal antibodies against complement 3 neoantigens for detection of immune complexes and complement activation. Relationship between immune complex levels, state of C3, and numbers of receptors for C3b. J Clin Invest (1985) 1.01
Circulating intercellular adhesion molecule-1 in patients with systemic sclerosis. Clin Immunol Immunopathol (1993) 1.00
CAMP response element modulator a expression in patients with systemic lupus erythematosus. Lupus (2006) 1.00
Dexamethasone inhibits human interleukin 2 but not interleukin 2 receptor gene expression in vitro at the level of nuclear transcription. J Clin Invest (1991) 1.00
Natural killer cells and interferon responses in patients with systemic lupus erythematosus. Clin Exp Immunol (1982) 0.99
NIH conference. Lupus nephritis. Ann Intern Med (1987) 0.99
Defective production of functional 98-kDa form of Elf-1 is responsible for the decreased expression of TCR zeta-chain in patients with systemic lupus erythematosus. J Immunol (2002) 0.98
Overexpression of HSP-70 inhibits the phosphorylation of HSF1 by activating protein phosphatase and inhibiting protein kinase C activity. FASEB J (1998) 0.96
Increased proto-oncogene expression in peripheral blood lymphocytes from patients with systemic lupus erythematosus and other autoimmune diseases. Arthritis Rheum (1986) 0.96
Cellular immune responses in systemic lupus erythematosus. Prog Allergy (1984) 0.95
Lymphocyte adhesion molecules in autoimmune rheumatic diseases: basic issues and clinical expectations. Clin Exp Rheumatol (1996) 0.95
Chronic lupus peritonitis with ascites. Ann Rheum Dis (1991) 0.94
Defective antigen-presenting cell function in patients with systemic lupus erythematosus. Arthritis Rheum (1996) 0.94
Nocebo in fibromyalgia: meta-analysis of placebo-controlled clinical trials and implications for practice. Eur J Neurol (2011) 0.94
Antiinflammatory effects of soluble complement receptor type 1 promote rapid recovery of ischemia/reperfusion injury in rat small intestine. Clin Immunol (1999) 0.93
Heterogeneous nuclear ribonucleoprotein D0 contains transactivator and DNA-binding domains. Biochem J (2000) 0.93
T cell signaling abnormalities in systemic lupus erythematosus are associated with increased mutations/polymorphisms and splice variants of T cell receptor zeta chain messenger RNA. Arthritis Rheum (2001) 0.93
Acute transverse myelitis and antiphospholipid antibodies in lupus. No evidence for anticoagulation. Eur J Neurol (2010) 0.92
Irinotecan as salvage chemotherapy for advanced small bowel adenocarcinoma: a series of three patients. J Chemother (2003) 0.91
Defective FcgammaRIIb1 signaling contributes to enhanced calcium response in B cells from patients with systemic lupus erythematosus. Clin Immunol (2001) 0.91
Immunohistological demonstration of transforming growth factor-beta isoforms in the skin of patients with systemic sclerosis. Clin Immunol Immunopathol (1993) 0.91
Spontaneous and pokeweed mitogen-induced plaque-forming cells in systemic lupus erythematosus. Clin Immunol Immunopathol (1981) 0.90
Myocardial performance and aortic elasticity are impaired in patients with ankylosing spondylitis. Scand J Rheumatol (2009) 0.90
Association of deficient type II protein kinase A activity with aberrant nuclear translocation of the RII beta subunit in systemic lupus erythematosus T lymphocytes. J Immunol (2000) 0.89
Prevalence of T cell receptor zeta chain deficiency in systemic lupus erythematosus. Lupus (2003) 0.89
Increased expression of functional Fas-ligand in activated T cells from patients with systemic lupus erythematosus. Autoimmunity (1997) 0.89
Effects of cholera toxin on human B cells. Cholera toxin induces B cell surface DR expression while it inhibits anti-mu antibody-induced cell proliferation. J Immunol (1990) 0.89
The association of systemic lupus erythematosus and myasthenia gravis. Postgrad Med J (1994) 0.89
Muscle involvement in systemic lupus erythematosus. JAMA (1981) 0.88
CD28 expression on T cell subsets in vivo and CD28-mediated T cell response in vitro in patients with rheumatoid arthritis. Arthritis Rheum (1995) 0.87
Transcriptional regulation of the complement receptor 2 gene: role of a heterogeneous nuclear ribonucleoprotein. J Immunol (1997) 0.87
Cross-linking of the Fas/APO-1 antigen suppresses the CD3-mediated signal transduction events in human T lymphocytes. J Immunol (1995) 0.87
Immunoregulatory disorders associated with hereditary angioedema. II. Serologic and cellular abnormalities. J Allergy Clin Immunol (1986) 0.87
Production of IgG and IgM autoantibody to the alternative pathway C3 convertase in normal individuals and patients with membranoproliferative glomerulonephritis. Clin Immunol Immunopathol (1990) 0.86
Decreased interleukin 2 inhibitor in sera of patients with autoimmune disorders. Clin Exp Immunol (1986) 0.86
A clinical and pathologic study of cerebrovascular disease in patients with systemic lupus erythematosus. Semin Arthritis Rheum (1986) 0.86
Psoriasiform lesions appearing in three patients with rheumatoid arthritis during therapeutic administration of abatacept, a selective inhibitor of T-cell costimulation. J Eur Acad Dermatol Venereol (2011) 0.86
Elevated in vivo expression of the costimulatory molecule B7-BB1 (CD80) on antigen presenting cells from a patient with SLE. Clin Exp Rheumatol (1997) 0.86
Cutaneous vasculitis associated with mixed cryoglobulinemia in adult Still's disease. Clin Exp Rheumatol (2003) 0.86
Serum concentrations of soluble intercellular adhesion molecule-1 and progress towards disease in patients infected with HIV. J Infect (1994) 0.86
Tuberculosis and granuloma formation in patients receiving anti-TNF therapy. Int J Tuberc Lung Dis (2006) 0.86
Suppressor T cells in systemic lupus erythematosus: lack of defective in vitro suppressor cell generation in patients with active disease. J Clin Lab Immunol (1982) 0.86
Aortic stiffness in systemic sclerosis is increased independently of the extent of skin involvement. Rheumatology (Oxford) (2004) 0.85
Evidence that production of autoantibody to the alternative pathway C3 convertase is a normal physiologic event. J Pediatr (1990) 0.85
Regulation of immunoglobulin secretion by factor H of human complement. Immunology (1985) 0.85
Soluble interleukin-2 receptor is a thyroid hormone-dependent early-response marker in the treatment of thyrotoxicosis. Clin Diagn Lab Immunol (1997) 0.84